bi 690517

Small moleculeexperimental

Clinical trial activity

17 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
10
Phase 2
7
Phase 3
4
Phase 4
0

Earliest trial started Sep 1, 2016 (NCT02891148)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@]1(CO)Cc2ncn(-c3ccc(C#N)c(Cl)c3)c2C(=O)O1
Mol. weight
317.73 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bi 690517

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07304817Phase 2Feb 28, 2026Boehringer Ingelheim, University of Groningen
NCT07133399Phase 1Sep 8, 2025Boehringer Ingelheim
NCT07064473Phase 3Jul 22, 2025Boehringer Ingelheim
NCT06926660Phase 2Jul 18, 2025Boehringer Ingelheim
NCT07035457Phase 1Jul 2, 2025Boehringer Ingelheim
NCT06935370Phase 3May 20, 2025Boehringer Ingelheim
NCT06647810Phase 1Nov 13, 2024Boehringer Ingelheim
NCT06531824Phase 3Oct 15, 2024Boehringer Ingelheim
NCT06424288Phase 3May 31, 2024Boehringer Ingelheim
NCT05731908Phase 1Feb 21, 2023Boehringer Ingelheim
NCT05515588Phase 1Sep 19, 2022Boehringer Ingelheim
NCT05182840Phase 2Jan 11, 2022Boehringer Ingelheim
NCT03608072Phase 1Aug 6, 2018Boehringer Ingelheim
NCT03165240Phase 1Aug 21, 2017Boehringer Ingelheim
NCT03206632Phase 1Jul 17, 2017Boehringer Ingelheim
NCT03100916Phase 1May 5, 2017Boehringer Ingelheim
NCT02891148Phase 1Sep 1, 2016Boehringer Ingelheim
Showing 17 of 17 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Boehringer IngelheimFor profit171632016
University of GroningenAcademic/Hospital1112026
2 organizations
Page 1 / 1